Editorial Commentary
Non-small cell lung cancer 2 cm or less: robotic segmentectomy sets the gold standard against non-surgical therapy
Abstract
Dr. Nguyen and colleagues presented a retrospective review of the long-term results of robotic anatomic segmentectomy for patients with clinically-staged T1a and T1bN0M0 non-small cell lung cancer (NSCLC) (1). This is a well-written paper with a timeline that spans from 2004–2013, allowing for a minimum follow-up of 5 years. It appears that follow-up is complete in all patients. If true this is an important feature that few studies (including all of ours) have been able to accomplish.